People with chronic chest pain who received a coronary sinus reducer (CSR)—a stent thought to increase the amount of oxygen-rich blood flowing to the heart muscle—experienced significant reductions in ...

ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant showed a symptom alleviation benefit in the small placebo-controlled ...

A recent state-of-the-art review overlooks a “safe and effective” therapy for patients with stable angina and no good treatment options, according to several cardiologists. The coronary sinus reducer ...

ATLANTA, GA — Despite failing to increase perfusion as hypothesized, a coronary sinus reducer (CSR) in a sham-controlled randomized trial meaningfully reduced angina and improved quality of life in ...

The coronary sinus reducer (CSR), an hourglass-shaped stent that narrows the coronary sinus to increase coronary sinus pressure, has shown some promise in treating patients with refractory angina. But ...

BOSTON, MA—One-year outcomes from an early feasibility study (EFS) show durable improvements in symptoms and quality of life in symptomatic heart failure (HF) patients treated with a novel coronary ...

Please provide your email address to receive an email when new articles are posted on . A coronary sinus reducer reduced the frequency of angina events for patients with significant CAD. However, the ...

A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for $13 billion, ended up providing some ...

Cardiac physiologic pacing, also known as cardiac resynchronization therapy, is indicated in patients with heart failure, reduced left ventricular ejection fraction (LVEF) of 50% or less, and either a ...

VahatiCor CEO Harry Rowland explains how the nitinol A-Flux reducer implant is designed to treat coronary microvascular ...